You are here: Industry Insights > AstraZeneca

News List

Circassia pulls plug on AZ agreement pharmatimes
April 10, 2020
Circassia Pharmaceuticals is pulling back from its development and commercialisation agreement with AstraZeneca for US commercial rights to COPD therapies Tudorza (aclidinium) and Duaklir (aclidinium/formoterol).
AstraZeneca begins efforts to identify antibodies against Covid-19 pharmaceutical-technology
April 10, 2020
AstraZeneca has begun research efforts focused on the identification and development of antibody therapies against Covid-19 coronavirus infection.
COVID-19 Testing Collaboration: AstraZeneca & GSK contractpharma
April 10, 2020
Big Pharma firms and the University of Cambridge collaborate to support UK national effort to boost COVID-19 testing.
AstraZeneca Announces Divestment of Movantik to RedHill Biopharma Complete americanpharmaceuticalreview
April 07, 2020
AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill).
AZ licences Movantik rights to RedHill pharmatimes
April 02, 2020
AstraZeneca has completed its deal to sublicense global rights to Movantik (naloxegol), (excluding Europe, Canada and Israel) to RedHill Biopharma.
FDA approves Imfinzi for extensive-stage SCLC pharmatimes
April 01, 2020
AstraZeneca has announced that Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) as 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).
AZ recruits ImaginAb in CD8 ImmunoPET deal pharmatimes
March 31, 2020
AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology.
Forxiga successful in DAPA-HF heart failure trial pharmatimes
March 31, 2020
New data from a sub-analysis of AstraZeneca’s Phase III DAPA-HF trial has shown that Forxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo.
AstraZeneca, Silence Therapeutics Announce siRNA Collaboration americanpharmaceuticalreview
March 31, 2020
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases.
FDA approves AstraZeneca’s Imfinzi for small cell lung cancer pharmaceutical-technology
March 31, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adults.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page